Soleno Therapeutics Target of Unusually High Options Trading (NASDAQ:SLNO)

Soleno Therapeutics, Inc. (NASDAQ:SLNO) saw some unusual options trading activity on Wednesday. Traders purchased 6,832 call options on the company. This represents an increase of 92% compared to the typical volume of 3,560 call options.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. TD Cowen downgraded shares of Soleno Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the company from $85.00 to $53.00 in a research report on Tuesday, April 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Cantor Fitzgerald downgraded shares of Soleno Therapeutics from an “overweight” rating to a “hold” rating and decreased their target price for the company from $123.00 to $53.00 in a research report on Monday, April 6th. Robert W. Baird downgraded shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Finally, Lifesci Capital downgraded shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $76.67.

Soleno Therapeutics Price Performance

Shares of Soleno Therapeutics stock traded up $0.01 during trading hours on Wednesday, reaching $52.93. The stock had a trading volume of 932,275 shares, compared to its average volume of 2,895,873. The stock’s 50 day moving average is $42.73 and its 200 day moving average is $46.54. The firm has a market capitalization of $2.76 billion, a PE ratio of 230.12 and a beta of -2.22. Soleno Therapeutics has a twelve month low of $29.43 and a twelve month high of $90.32. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to analyst estimates of $88.55 million. Equities analysts expect that Soleno Therapeutics will post 3.67 earnings per share for the current fiscal year.

Key Stories Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Company fundamentals and recent results provide some support — Soleno reported an EPS beat in its last quarter (Feb. 25) and shows strong liquidity ratios, which reduces immediate solvency risk for investors.
• Neutral Sentiment: Broker consensus sits at an average “Hold,” reflecting mixed analyst views rather than a buy/sell conviction. Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of “Hold” by Brokerages
• Neutral Sentiment: Market is watching for the company’s upcoming quarterly earnings announcement — results or forward guidance could move the stock independently of the litigation headlines. Soleno Therapeutics (SLNO) Expected to Announce Quarterly Earnings on Wednesday
• Negative Sentiment: Multiple shareholder‑rights firms have filed or are soliciting claimants in a securities class action covering purchases from March 26, 2025 to Nov 4, 2025 and are urging investors to file by the May 5, 2026 lead‑plaintiff deadline — this increases legal overhang and short‑term selling pressure. SOLENO DEADLINE TODAY: ROSEN Announces Lead Plaintiff Deadline Pomerantz Investor Alert Hagens Berman Deadline Alert
• Negative Sentiment: High volume of firm solicitations and media notices magnifies perception of risk — even if claims are routine, litigation can mean legal costs, management distraction, and uncertain timing for resolution, which tends to cap near‑term upside.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Raymond James Financial Inc. acquired a new position in shares of Soleno Therapeutics in the second quarter worth about $25,000. Danske Bank A S acquired a new position in shares of Soleno Therapeutics in the third quarter worth about $27,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Soleno Therapeutics in the third quarter worth about $37,000. Global Retirement Partners LLC raised its position in shares of Soleno Therapeutics by 519.0% during the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after purchasing an additional 519 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Soleno Therapeutics during the 3rd quarter worth about $47,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.